1.Treatments for resectable esophageal cancer: from traditional systemic therapy to immunotherapy.
Yan YAN ; Xijia FENG ; Chengqiang LI ; Toni LERUT ; Hecheng LI
Chinese Medical Journal 2022;135(18):2143-2156
Esophageal cancer (EC) has a high incidence and poor prognosis. The two major histological types, squamous cell carcinoma and adenocarcinoma, differ in their epidemiology and treatment options. Patients with locally advanced EC benefit from multimodal therapy concepts including neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy, and perioperative chemotherapy. Currently, immunotherapy for the solid tumor is a hot spot. Treatment with adjuvant immune checkpoint inhibitors (ICIs) is the first immunotherapy for resectable EC listed in the latest National Comprehensive Cancer Network Guidelines for the Esophageal and Esophagogastric Junction Cancers. Recent clinical trials have established ICIs for three treatment models of resectable EC. Their short-term results demonstrated ideal efficacy and tolerable toxicity, though some concerns remain. This review summarizes the novel data on the ICIs for resectable EC and lists the registered related clinical trials. Hopefully, this review can provide a reference for ongoing research on the treatment options for resectable EC.
Humans
;
Esophageal Neoplasms/pathology*
;
Esophagogastric Junction/pathology*
;
Neoadjuvant Therapy/methods*
;
Adenocarcinoma/drug therapy*
;
Immunotherapy
2.Solitary spleen metastasis of endometrial carcinoma: a case report.
Chinese Journal of Cancer 2010;29(1):30-31
Adenocarcinoma
;
drug therapy
;
pathology
;
secondary
;
surgery
;
Chemotherapy, Adjuvant
;
Endometrial Neoplasms
;
drug therapy
;
pathology
;
surgery
;
Female
;
Humans
;
Hysterectomy
;
Middle Aged
;
Splenectomy
;
Splenic Neoplasms
;
drug therapy
;
pathology
;
secondary
;
surgery
3.Extensive acute lung injury following limited thoracic irradiation: radiologic findings in three patients.
Jung Hwa HWANG ; Kyung Soo LEE ; Koun Sik SONG ; Hojoong KIM ; O Jung KWON ; Tae Hwan LIM ; Yong Chan AHN ; In Wook CHOO
Journal of Korean Medical Science 2000;15(6):712-717
The aim of our study was to describe the radiologic findings of extensive acute lung injury associated with limited thoracic irradiation. Limited thoracic irradiation occasionally results in acute lung injury. In this condition, chest radiograph shows diffuse ground-glass appearance in both lungs and thin-section CT scans show diffuse bilateral ground-glass attenuation with traction bronchiectasis, interlobular septal thickening and intralobular smooth linear opacities.
Acute Disease
;
Adenocarcinoma/radiotherapy
;
Adenocarcinoma/pathology
;
Adenocarcinoma/drug therapy
;
Adenocarcinoma/complications*
;
Carcinoma, Squamous Cell/radiotherapy
;
Carcinoma, Squamous Cell/pathology
;
Carcinoma, Squamous Cell/drug therapy
;
Carcinoma, Squamous Cell/complications*
;
Journal Article
;
Human
;
Lung/radiation effects*
;
Lung/pathology
;
Lung Neoplasms/radiotherapy
;
Lung Neoplasms/pathology
;
Lung Neoplasms/drug therapy
;
Lung Neoplasms/complications*
;
Male
;
Middle Age
;
Radiation Injuries/radiography
;
Radiation Injuries/pathology
;
Radiation Injuries/etiology*
;
Thorax/radiation effects
4.Clinicopathological features of early gastric cancer after Helicobacter pylori eradication.
Wei Hua HOU ; Xin Zhao WANG ; Zhong Yue SHI ; Fu Lin LI ; Zeng Hong FANG ; Xiao Li SUN ; Yan Feng LIU ; Li Na WANG ; Mu Lan JIN
Chinese Journal of Pathology 2022;51(8):701-707
Objective: To investigate the clinicopathological features of early gastric cancers after Helicobacter pylori (H. pylori) eradication. Methods: The clinical data of 26 cases of gastric cancer that were diagnosed after H. pylori eradication and 45 cases without H. pylori eradication in the 989 Hospital of the Joint Logistics Support Force of the People's Liberation Army (the former 152 Hospital), Pingdingshan, China from 2013 to 2021 were collected. The histological, immunophenotypic and clinical characteristics of the two groups were compared, and discussed with review of the related literature. Results: Among the gastric cancer patients with H. pylori eradication, there were 20 males and 6 females with a median age of 65 years (range 53 to 77 years). The cancer involved the upper part of the stomach in 12 cases, the middle part of the stomach in 4 cases, and the lower part of the stomach in 10 cases. The median diameter of the tumors was 12 mm (range 4-29 mm). According to the Paris Classification, 4 cases were 0-Ⅱa, 4 cases were 0-Ⅱb, 18 cases were 0-Ⅱc. White light endoscopy showed that the lesions were reddish to yellowish. The lesion boundary was clear in 12 cases and was unclear or gastritis-like changes in 14 cases, while the irregular microvascular structure and microsurface structure, as well as the relatively visible spinous boundary, were visible under narrow-band imaging. There were 20 cases of well-differentiated tubular adenocarcinoma, 4 cases of highly to moderately differentiated tubular adenocarcinoma, and 2 cases of well-differentiated tubular adenocarcinoma with papillary adenocarcinoma. Compared with gastric cancers without H. pylori eradication, gastric cancers diagnosed after H. pylori eradication was associated with lower nucleus-cytoplasm ratio (<50%), normal epithelial coverage on the cancer surface, mild atypical epithelial coverage on the cancer surface, elongation of non-cancerous glands in the cancer tissue and subepithelial progression of cancerous glands were higher (P<0.05). The cellular immunophenotypes were gastric type in 6 cases, intestinal type in 4 cases and gastrointestinal mixed type in 16 cases. Conclusions: The early gastric cancers diagnosed after H. pylori eradication are more subtle clinically and mostly well-differentiated tubular adenocarcinoma. The important morphological features of gastric cancer diagnosed after H. pylori eradication are decreased cytological atypia and overlying normal epithelium or mildly atypical epithelium of the cancer. Understanding and recognizing these morphological features are helpful to make correct endoscopic and pathological diagnoses.
Adenocarcinoma/pathology*
;
Aged
;
Female
;
Gastric Mucosa/pathology*
;
Helicobacter Infections/drug therapy*
;
Helicobacter pylori
;
Humans
;
Male
;
Middle Aged
;
Stomach Neoplasms/drug therapy*
5.A Case of Synchronous Early Gastric Cancer and Diffuse Large B Cell Lymphoma Treated with Endoscopic Submucosal Dissection and Chemotherapy.
Jae Hyun PARK ; Jae Young JANG ; Yong Duck CHO ; Seok Ho DONG ; Hyo Jong KIM ; Byung Ho KIM ; Young Woon CHANG
The Korean Journal of Gastroenterology 2012;59(5):377-381
Among malignant tumors of the stomach, adenocarcinoma takes up about 95% and the remaining are mostly lymphomas, being less than 5%. The majority of lymphomas are B cell lymphomas, and the most common types are low-grade B cell lymphoma of mucosa-associated lymphoid tissue and diffuse large B cell lymphoma (DLBL). The synchronous occurrence of adenocarcinoma and lymphoma in the stomach is being reported rarely. Especially the concurrence of adenocarcinoma and DLBL is very scarce and less than 10 cases have been reported inside and outside this country. In the past, the general treatment for cases of concurrence of adenocarcinoma and DLBL when surgery is possible according to cancer stages was gastrectomy, followed by single or combined chemotherapy and radiation treatment. However, when considering that most cases of concurrent adenocarcinoma were early gastric cancer which is limited to the mucosa, endoscopic submucosal dissection (ESD) can become an alternative treatment method for gastrectomy. We report the experience with chemotherapy and ESD done together instead of surgery, in patients concurrently diagnosed with early gastric cancer and gastric lymphoma.
Adenocarcinoma/*drug therapy/surgery
;
Anti-Bacterial Agents/therapeutic use
;
Antineoplastic Agents/therapeutic use
;
Drug Therapy, Combination
;
Helicobacter Infections/drug therapy
;
Humans
;
Lymphoma, Large B-Cell, Diffuse/*drug therapy/pathology
;
Male
;
Middle Aged
;
Stomach Neoplasms/*drug therapy/surgery
6.Clinical analysis of 215 elderly patients with cervical cancer.
Min CHENG ; Ling-ying WU ; Wen-hua ZHANG ; Man-ni HUANG ; Rong ZHANG
Chinese Journal of Oncology 2009;31(5):388-391
OBJECTIVETo investigate the clinical features, treatment outcomes and possible prognostic factors in elderly patients with cervical cancer.
METHODSClinical data of 215 elderly women (> or = 65-years-old) with cervical cancer were retrospectively analyzed. Most patients (89.3%) had advanced stage ( II b-IV) disease. Eight of the 215 patients (3.7%) underwent surgical treatment, and six of those received postoperative radiotherapy. 133 patients received radiotherapy alone, and 74 patients underwent concurrent chemotherapy and radiotherapy.
RESULTSThe median follow-up time was 48 months (range: 12-102 months). The overall 5-year survival rate was 63.7%. The 5-year survival rate for stage I, II, III, IV were 83.2%, 76.4%, 39.0% and 0, respectively. There was no significant difference in 5-year survival rate between patients treated with concurrent chemotherapy combined with radiotherapy and radiotherapy alone. In multivariate analysis, lymph node metastasis, advanced stage, non-squamous histologies and poor differentiation were all negative prognostic factors for the overall survival.
CONCLUSIONThe treatment strategy for elderly cervical cancer patients should be individually planned according to the disease stage and performance status of the patients. Usually, one radical therapy modality can be chosen, and combined modality therapy is not suggested.
Adenocarcinoma ; drug therapy ; pathology ; radiotherapy ; surgery ; Adenocarcinoma, Clear Cell ; drug therapy ; pathology ; radiotherapy ; surgery ; Aged ; Antineoplastic Agents ; therapeutic use ; Carcinoma, Squamous Cell ; drug therapy ; pathology ; radiotherapy ; surgery ; Cisplatin ; therapeutic use ; Combined Modality Therapy ; Female ; Follow-Up Studies ; Humans ; Lymphatic Metastasis ; Neoplasm Staging ; Retrospective Studies ; Survival Rate ; Uterine Cervical Neoplasms ; drug therapy ; pathology ; radiotherapy ; surgery ; Young Adult
7.Advance in pulmonary adenocarcinoma with micropapillary pattern.
Jing ZHANG ; Zhi-yong LIANG ; Tong-hua LIU
Chinese Journal of Pathology 2011;40(3):202-205
Adenocarcinoma
;
drug therapy
;
genetics
;
metabolism
;
pathology
;
surgery
;
Adenocarcinoma, Bronchiolo-Alveolar
;
drug therapy
;
genetics
;
metabolism
;
pathology
;
surgery
;
Adenocarcinoma, Papillary
;
metabolism
;
pathology
;
Cadherins
;
metabolism
;
Diagnosis, Differential
;
Genes, erbB-1
;
genetics
;
Humans
;
Lung Neoplasms
;
drug therapy
;
genetics
;
metabolism
;
pathology
;
surgery
;
Lymphatic Metastasis
;
Mucin-1
;
metabolism
;
Mutation
;
Neoplasm Invasiveness
;
beta Catenin
;
metabolism
8.Modification of adriamycin-induced cytotoxicity by recombinant human interferon-gamma and/or verapamil in human stomach cancer cells.
Weon Seon HONG ; Chang Min KIM ; Choon Taek LEE ; Jhin Oh LEE ; Tae Woong KANG
Journal of Korean Medical Science 1992;7(3):236-240
Recombinant human-interferon-gamma (rH-IFN-gamma) and verapamil (VRP), either alone or in combination, were evaluated in MTT assay for their modification effects on adriamycin-induced cytotoxicity against MKN-45, human stomach adenocarcinoma cells. VRP as a single agent did not inhibit the survival of MKN-45 at doses of up to 5.0 micrograms/ml. The survival of MKN-45 was inhibited by rH-IFN-gamma dose-dependently and further inhibited by the addition of VRP. However, the maximum growth inhibition of MKN-45 in any combination treatment with rH-IFN-gamma and VRP was less than 50% except in the highest concentration combinations (% survival: 47.9% at 10(4) U/ml of rH-IFN-gamma and 3.0 micrograms/ml of VRP). Adriamycin caused a concentration-dependent cytotoxicity and its cytotoxicity was significantly enhanced by the addition of rH-IFN-gamma and further enhanced by the combined use of rH-IFN-gamma and VRP. The modification effects of rH-IFN-gamma and VRP on adriamycin-induced cytotoxicity were evaluated in terms of modification index (MI), demonstrating that rH-IFN-gamma significantly increased in adriamycin-induced cytotoxicity and that the combined use of rH-IFN-gamma and VRP enhanced the adriamycin-induced cytotoxicity to a greater extent than did rH-IFN-gamma alone: MI values at 10(2) U/ml and 10(3) U/ml of rH-IFN-gamma were 1.7 and 3.1, respectively; those at 1.5 micrograms/ml and 3.0 micrograms/ml of VRP in the presence of 10(3) U/ml of rH-IFN-gamma were 4.4 and 6.0, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
Adenocarcinoma/*drug therapy/pathology
;
Antineoplastic Combined Chemotherapy Protocols/pharmacology
;
Cell Survival/drug effects
;
Doxorubicin/*pharmacology
;
Drug Interactions
;
Drug Resistance
;
Drug Screening Assays, Antitumor
;
Humans
;
Interferon-gamma/*pharmacology
;
Recombinant Proteins
;
Stomach Neoplasms/*drug therapy/pathology
;
Tumor Cells, Cultured
;
Verapamil/*pharmacology
10.A Case Report of Advanced Lung Adenocarcinoma Harboring KRAS Mutation Treated with Anlotinib.
Yudong SU ; Zhaoting MENG ; Xiaoyan XU ; XinYue WANG ; Ran ZUO ; Yunxia HOU ; Kai LI ; Peng CHEN
Chinese Journal of Lung Cancer 2018;21(5):428-430
In recent years, the number of advanced non-small cell lung cancer (NSCLC) patients has gradually increased, and the treatment methods have also been significantly increased. However, there are no standard treatment plans at home and abroad for third-line and above patients who are refractory to targeted therapy epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) or chemotherapy. The clinical treatment effect is also not satisfactory. Anlotinib is a novel TKI targeting the vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR) and c-Kit. ALTER0303 trail, phase III study has demonstrated that Anlotinib significantly prolonged overall survival (OS) and progression-free survival (PFS) in advanced NSCLC patients as 3rd line treatment.Here we report a case of advanced lung adenocarcinoma harboring KRAS mutation treated with Anlotinib.
.
Adenocarcinoma
;
drug therapy
;
enzymology
;
genetics
;
pathology
;
Adenocarcinoma of Lung
;
Aged
;
Antineoplastic Agents
;
therapeutic use
;
Humans
;
Indoles
;
therapeutic use
;
Lung Neoplasms
;
drug therapy
;
enzymology
;
genetics
;
pathology
;
Male
;
Mutation
;
Proto-Oncogene Proteins p21(ras)
;
genetics
;
metabolism
;
Quinolines
;
therapeutic use